Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Cost-Effectiveness Analysis of Trastuzumab Deruxtecan Versus Trastuzumab Emtansine for Patients With Human Epidermal Growth Factor Receptor 2 Positive Metastatic Breast Cancer in the United States.
Value Health
February 2024
Department of Health Policy and Management, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA.
Objectives: To assess the cost-effectiveness of trastuzumab deruxtecan compared with trastuzumab emtansine as second-line therapy for patients with human epidermal growth factor receptor 2 positive metastatic breast cancer from a US healthcare sector perspective.
Methods: A 3-state partitioned survival model was developed to estimate the cost-effectiveness of trastuzumab deruxtecan compared with trastuzumab emtansine. For both treatments, modeled patients were administered treatment intravenously every 3 weeks indefinitely or until disease progression.
Comparative assessment of quality of life of patients with schizophrenia attending a community psychiatric centre and a psychiatric hospital.
Ghana Med J
June 2019
Department of Psychiatry, Ekiti State University Teaching Hospital, Ado-Ekiti, Ekiti State, Nigeria.
Background: Over the past few decades, there has been an emphasis on the de-institutionalisation of psychiatric care with a focus on community care. With Quality of Life (QoL) as an outcome measure, this study compared the QoL of patients with schizophrenia attending a psychiatric hospital and a community psychiatric centre.
Design: This was a cross-sectional study in two psychiatric facilities.
Projecting the cost, utilization, and patient care impact of prescribing extended release non-abuse-deterrent opioids to chronic pain patients.
J Opioid Manag
April 2018
Pfizer Inc., Durham, North Carolina.
Objectives: To estimate healthcare resource utilization, associated costs, and number needed to harm (NNH) from a physician's decision to prescribe extended-release (ER) non-abuse-deterrent opioids (non-ADO) as compared to ER ADOs in a chronic pain population.
Design: A 12-month probabilistic simulation model was developed to estimate the reduction of misuse and/or abuse from a physician's prescribing decisions for 10,000 patients. Model inputs included probabilities for opioid misuse and/or abuse-related events, opioid discontinuation, and switching from ADO to non-ADO.
Much Ado About Nothing? The Relationship of Institutional Percutaneous Coronary Intervention Volume to Mortality.
Circ Cardiovasc Qual Outcomes
March 2017
From the Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX (D.J.K.); and Interventional Cardiology Group, Munroe Regional Medical Center, Ocala, FL (J.A.B.).
Radiology in pioneer accountable care organizations: much ado about nothing?
J Am Coll Radiol
February 2015
Weill Cornell Medical College, New York, New York.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!